Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: A randomized clinical trial comparing two regimens

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3408-3417

  Pappa, Helen M ^a   Mitchell, Paul D ^a   Jiang, Hongyu ^a   Kassiff, Sivan ^a   Filip Dhima, Rajna ^a   DiFabio, Diane ^a   Quinn, Nicolle ^a   Lawton, Rachel C ^b   Bronzwaer, M E S ^c   Koenen, Mirjam ^c   Gordon, Catherine M ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCIUM; CREATININE; ERGOCALCIFEROL; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INTERLEUKIN 6; PHOSPHORUS; 25-HYDROXYVITAMIN D; VITAMIN; VITAMIN D;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BONE PAIN; CALCIFICATION; CALCIUM BLOOD LEVEL; CHILD; CONSTIPATION; CONTROLLED STUDY; CREATININE URINE LEVEL; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PATIENT COMPLIANCE; PEDIATRIC HOSPITAL; PHOSPHATE BLOOD LEVEL; PHOTOSENSITIVITY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN PRURITUS; SPRING; SUMMER; THIRST; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULCERATIVE COLITIS ACTIVITY INDEX; UNITED STATES; URINARY FREQUENCY; VITAMIN SUPPLEMENTATION; VOMITING; WEAKNESS; WINTER; XEROSTOMIA; ANALOGS AND DERIVATIVES; BLOOD; COLITIS, ULCERATIVE; DIET SUPPLEMENTATION; METABOLISM; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; QUESTIONNAIRE; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DIETARY SUPPLEMENTS; ERGOCALCIFEROLS; FEMALE; HUMANS; MALE; QUESTIONNAIRES; TREATMENT OUTCOME; ULTRAVIOLET RAYS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84907190915     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4218     Document Type: Article

References (40)

1. Harpavat M, Greenspan SL, O'Brien C, Chang CC, Bowen A, Keljo DJ. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J Pediatr Gastroenterol Nutr. 2005;40: 295-300.
2. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76: 315-325.
3. Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys. 2012;523: 103-106.
4. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1-,25-dihydroxyvitamin D3 target the TNF-pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35: 217-224.
5. Verlinden L, Leyssens C, Beullens I, et al. The vitamin D analog TX527ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease. J Steroid Biochem Mol Biol. 2013; 136: 107-111.
6. Goff JP, Koszewski NJ, Haynes JS, Horst RL. Targeted delivery of vitamin D to the colon using -glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease.AmJ Physiol Gastrointest Liver Physiol. 2012;302: G460-G469.
7. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88: 491S-499S.
8. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122: 398-417.
9. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
10. Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006;260: 245-254.
11. KDOQI Work Group. Clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary.AmJ Kidney Dis. 2009;53: S11-S104.
12. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53: 11-25.
13. Tangpricha V, Kelly A, Stephenson A, et al.Anupdate on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97: 1082-1093.
14. Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97: 2134-2142.
15. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85: 6-18.
16. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44: 653-674.
17. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12: 439-447.
18. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70: 439-444.
19. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133: 423-432.
20. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110: 353-356.
21. Srivastava M, Zurakowski D, Cheifetz P, Leichtner A, Bousvaros A. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33: 548-553.
22. Sack U, Burkhardt U, Borte M, Schadlich H, Berg K, Emmrich F. Age-dependent levels of select immunological mediators in sera of healthy children. Clin Diagn Lab Immunol. 1998;5: 28-32.
23. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999; 17: 1019-1025.
24. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites: Serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8: 222-230.
25. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73: 288-294.
26. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitaminDconcentration.AmJ Clin Nutr. 2008;87: 1952-1958.
27. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77: 204-210.
28. Shroff R, Wan M, Gullett A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathy-roidism: a randomized trial. Clin J Am Soc Nephrol. 2012;7: 216-223.
29. Farraye FA, Nimitphong H, Stucchi A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis. 2011;17: 2116-2121.
30. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53: 1129-1136.
31. So NP, Osorio AV, Simon SD, Alon US. Normal urinary calcium/creatinine ratios in African-American and Caucasian children. Pediatr Nephrol. 2001;16: 133-139.
32. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6: 583-588.
33. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104: 1285-1292.
34. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr. 2003;23: 117-145.
35. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford). 2010;49: 1466-1471.
36. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-A randomized double-blind placebocontrolled study. Aliment Pharmacol Ther. 2010;32: 377-383.
37. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15: 1656-1662.
38. Hollis BW, Wagner CL. The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab. 2013; 98: 4619-4628.
39. Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. VitaminDand DBP: the free hormone hypothesis revisited [published online October 3, 2013]. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2013.09.012.
40. van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H. Cholecalciferol loading dose guideline for vitamin Ddeficient adults. Eur J Endocrinol. 2010;162: 805-811.